UPDATE: Goldman Sachs Lowers MAKO Surgical's PT

According to a research report published this morning, Goldman Sachs has lowered MAKO Surgical's MAKO PT from $42 to $36. In the report, Goldman Sachs said, "We maintain our Buy rating on MAKO shares following meetings with management and physicians at the Current Concepts in Joint Replacement (CCJR) meeting. We see 61% upside from current levels and continue to view MAKO as an attractive fundamental and strategic asset. By and large, our diligence suggests several of the factors negatively impacting MAKO's 1Q2012 results are likely to prove transient (timing of order placements, procedure ramp), and execution should improve through the balance of the year. Shares have underperformed the Russell 2000 by 4,150bp since reporting 1Q2012 results, creating an even more compelling entry point." MAKO Surgical closed yesterday at $22.42.